

## The ToxCast 320 Chemical Library in Cultures of Primary Human Hepatocytes:

## qNPAs as Windows into Chemical-Induced Hepatocyte Biology

Stephen S. Ferguson, Ph.D.



Tissues and Organs: a text of scanning electron microscopy, Kessel, RG and Kardon, RH, 1979

2



Invitrogen Corporation Invitrogen Proprietary & Confidential

### **Primary Hepatocyte Culture Systems**



Conventional monolayer

Sandwich culture 1

Sandwich culture 2

## Primary Cultures of Human Hepatocytes: Effective Models of the Liver

- Gold Standard in vitro model system for human liver
- Metabolically competent model system (metabolite effects)
- Effective models of hepatic metabolism (e.g. Phase I, Phase II, CL<sub>INT</sub>)
- Hepatic transporter function modeled (uptake and efflux) to assess exposure
- Long-term (days-weeks) culture can model chronic exposure endpoints
- Multi-donor studies possible to assess interindividual variability and correlate genetic polymorphism effects
- Induction/suppression: Retain liver-like cell signaling (e.g. nuclear receptor expression) to model speciesspecific induction





## Liver Function: Why Is It Important to Assess Induction-Adaptive response?

- Chronic receptor activation (e.g. CAR) linked with cancer
- Xenobiotic toxicity potentiated by induced/suppressed metabolism
- Induction relevance to cytotoxicity (cause or biomarker)
- Perturbation of endogenous chemical (e.g. steroid) homeostasis
- Failure of therapeutic drugs (e.g. OC's, epilepsy, HIV)

5

• Altered cellular exposure over time (altered transport and/or metabolism)



Time



# **General Mechanisms of P450 Induction**

- mRNA stabilization
- Protein stabilization
- Receptor-mediated transcriptional activation



Coordinates: Kumar R, Thompson EB (1999). "The structure of the nuclear hormone receptors". Steroids 64 (5): 310-9



### **Important Hepatic Receptor Pathways**



Others: LXR, PPARγ, VDR, ER, TR, NRF-2...

7 -

invitrogen corporation \_\_\_\_\_\_ Invitrogen Proprietary & Confidential

### Induction and Receptor Regulation of Hepatic Transport as well as Phase I and II metabolism



## Questions

- How do we assess a chemical's potential to modulate these hepatic pathways?
  - mRNA

9

- Protein
- Functional activity
- What receptor pathways appear to be affected, and how do we study in a metabolically-competent, liver-like system
  - Sentinel gene targets and selective PC inducers
  - Receptor antagonist studies
  - Knock-down of receptors
  - Transfection of receptor reporters into hepatocytes
- How do we assess thousands of chemicals
  - high throughput (≥96-well) cultures of primary hepatocytes
  - Multiplexed, high content, and complementary endpoints
- What are the concentration-response and time-response profiles of these effects?
- How do we use time as a tool to characterize the adaptive responses (e.g. cause/effect) and probe the potential for human liver interactions?

# **Experimental Study Design**

- Cultures of primary human hepatocytes
- 96-well format
- 6 reference chemicals (known receptor activators)
- ToxCast 320 chemical library
- Endpoints
  - qNPA
    - 14 gene targets important for liver biology
      - 6 P450 genes
      - 4 transporter genes
      - 3 phase II metabolism genes
      - 1 cholesterol synthesis gene
      - 2 endogenous control genes
  - CYP1A Enzymatic Activity (EROD)
  - Cell morphology (Cell Health)
- Dose-response curves (≥ 5 concentrations)
- 4 time points (6, 24, and 48 hours)





Image cultures

EROD Assays

qNPA detection

Data Analysis

### How the qNPA assay works...



## Hepatic Expression Systems (HES): High Throughput RNAse Protection Assay (Human)



Target Genes Receptor Pathways AhR CAR PXR PPARα FXR

Target Genes Category CYP450 (6) Transporter (4) Phase II Metabolism (3) Endogenous Metabolism (7) 'Housekeeping' gene (2)

**Cellz**Direct<sup>™</sup>

Invitrogen Corporation Invitrogen Proprietary & Confidential

## Plate Image

Media									
DMSO									::::
Rif									<b>.</b>
СІТСО									
3-MC	 				 GAR	PDH AB	GB1 (C	(P1A1) C	YP1A2
Fen						TA2 AB	cB11 C	/PZB6 SI	JLT2A1
CDCA					C/P	209 06	TIAI HA	AGCS2	ABCG2
13 ——	 1 minute exp	osure 50	0,000 cells/well	used	 CYPE	2с19 су	P3A4 SL	CO1B1	ACTIN

## **EROD assay: CYP1A Enzymatic Activity**



## **Cell Morphology Assessments**



### Data Analysis

- Compiling >300,000 data points into viewable database
- Developed data analysis tools to cluster data across both concentration- and time-response (k-means) in 210-dimensional space
- Curve fitting across concentration-response
  - $EC_{50}$
  - $E_{max}$
  - $E_{min}$
  - Hill slope
- Statistically Significant Responses (f-test)
- Choice of Reference Chemicals (Z-factor)
- Correlation Analyses (e.g. EROD, gene-to-gene, etc...)
- Time Effects: Ongoing





•Fit using non-linear least squares in the R statistical language



EC50=0.17459 | R^2: 0.97319



EC50=0.15329 | R^2: 0.98793

invitrogen corporation \_\_\_\_\_ Invitrogen Proprietary & Confidential

## **Reference Chemical Selection**

•Why do this:

•Choice based on lit vs. data here

•Genes not well characterized with prototypical inducers accounted for through study data

•Z-factor<sup>1:</sup> 
$$1 - \left[\frac{3*(\sigma_p + \sigma_n)}{|\mu_p - \mu_n|}\right]$$

 $\bullet~\sigma_p\,$  ,  $\sigma_n$  : Positive and Negative control standard deviations

•  $\mu_p$  ,  $\mu_n$  : Positive and Negative control  $E_{max}$  averages

Z-factor	Evaluation				
1.0	Ideal. Large dynamic range and tiny standard deviation. A Z-factor can not ever actually equal 1 and is a theoretical Limit				
0.5 < Z-factor < 1	Excellent Assay.				
0 < Z-factor <0.5	Marginal Assay				
Z-factor < 0	Positive and Negative controls overlap.				

<sup>1</sup>Zhang JH, Chung TD, Oldenburg KR, "A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays." *J Biomol Screen.* **1999**;4(2):67-73





#### **Reference Chemical Concentration- and Time-Response Curves**



Concentration (uM)





CDCA-ABCB11



10-20 20-30 30-40 40-50 50-60 60-70 70-80 80-90 >90

**CellzDirect**<sup>\*\*</sup> invitrogen corporation Invitrogen Proprietary & Confidential

**RIF-CYP3A4** 







invitrogen corporation \_\_\_\_\_ Invitrogen Proprietary & Confidential

24



RIF-SULT2A1



<10 10-20 20-30 30-40 40-50 50-60 60-70 70-80 80-90 >90

invitrogen corporation \_\_\_\_\_ Invitrogen Proprietary & Confidential



Hignlight Table								
) r	Gene 2 (time)							
0.9445	CYP1A2 (24)							
0.9053	SLCO1B1 (48)							
0.8859	ABCG2 (48)							
0.8645	SLCO1B1 (48)							
0.8610	CYP1A2 (48)							
0.8515	ABCG2 (48)							
0.8312	CYP1A2 (24)							
0.8220	CYP1A2 (48)							
0.8159	CYP1A1 (48)							
0.8009	CYP1A1 (24)							
0.7963	CYP1A1 (48)							
0.7940	CYP1A1 (48)							
0.7801	SULT2A1 (48)							
0.7660	SULT2A1 (48)							
0.7613	CYP1A2 (48)							
0.7555	SULT2A1 (48)							
0.7519	CYP1A2 (48)							
0.6415	UGT1A1 (48)							
0.6171	CYP3A4 (6)							
0.6156	CYP3A4 (48)							
0.5924	CYP3A4 (24)							
0.5896	CYP3A4 (48)							
0.5522	CYP2B6 (48)							
-0.2103	HMGCS2 (6)							
	r   0.9445   0.9053   0.8859   0.8645   0.8610   0.8515   0.8515   0.8220   0.8159   0.8009   0.7963   0.7940   0.7801   0.7660   0.7555   0.7519   0.6415   0.6171   0.6156   0.5924   0.5896   0.5522							



Note time similarities are pronounced

Invitrogen Proprietary & Confidential

27

×

## **Suppression**

- Only ~550 suppression responses relative to thousands of observed induction responses at various time points and doses
- HMGCS2 gene was the most frequently suppressed gene followed by others including CYP2C9



### **Changes in Cell Morphology in Response to Chemical Exposure**





#### Induction vs. % Chemicals with Apparent Cytotoxicity

### **Representative Efficacious ToxCast 320 CYP1A1 Inducers**



Representative ToxCast Chemicals for Potency and Efficacy for CYP1A1 at 48hrs

### **Representative Efficacious ToxCast 320 CYP1A2 Inducers**



Representative ToxCast Chemicals for Potency and Efficacy for CYP1A2 at 48hrs

### **Representative Efficacious ToxCast 320 CYP2B6 Inducers**

Donor 776 120 Donor 778 EC50 = 2.511 uM || % Efficacy 100.4% EC50 = 16.631 uM || % Efficacy 77.13% EC50 = 1.548 uM || % Efficacy 217.3% EC50 = 15.78 uM || % Efficacy 204.4% EC50 = 0.372 uM || % Efficacy 104.3% EC50 = 0.769 uM || % Efficacy 157.7% 8 % Efficacy 100.% Phenobarbitol EC50 = 404.31 uM Phenobarbitol EC50 = 617.24 uM || % Efficacy 100.0% Fold Induction / 48hr Controls 8 8 \$ 20 0 1e-02 1e+02 1e+00 **Cellz**Direct<sup>™</sup> log Concentration (uM)

Representative ToxCast Chemicals for Potency and Efficacy for CYP2B6 at 48hrs

### **Representative Efficacious ToxCast 320 CYP3A4 Inducers**

Representative ToxCast Chemicals for Potency and Efficacy for CYP3A4 at 48hrs



34

## Representative ToxCast 320 UGT1A1 & HMGCS2 Inducers

Representative ToxCast Chemicals for Potency and Efficacy for UGT1A1 at 48hrs

Representative ToxCast Chemicals for Potency and Efficacy for HMGCS2 at 48hrs



### **Efficacious ToxCast 320 Responses**

Most Efficacious Compounds for CYP1A1 | 48hrs | Donor 776

Most Efficacious Compounds for GSTA2 | 48hrs | Donor 778



Increasing Concentration -->

Increasing Concentration -->

invitrogen corporation \_\_\_\_\_ Invitrogen Proprietary & Confidential

#### Representative dose-response curves

Most Efficacious Compounds for ABCG2 | 48hrs | Donor 778

#### Most Efficacious Compounds for SLCO1B1 | 48hrs | Donor 776



invitrogen corporation \_\_\_\_\_ Invitrogen Proprietary & Confidential

## **Summary & Next Steps**

•Effectively cultured primary human hepatocytes on 218 plates in 96-well format across 5 chemical concentrations and 4 time points within 2 week period

•Assessed endpoints of cell morphology, EROD, and multiplexed qNPA for 14 gene targets and completed experiments within 6 weeks to generate over 300,000 publication-quality data points

•Profiled and clustered the ToxCast 320 chemicals' relative receptor activators for the AhR, CAR, PXR, FXR, and PPARα pathways

•Fit over 14,000 dose response curves to generate  $EC_{50}$ ,  $E_{max}$ ,  $E_{min}$ , and Hill slopes for qNPA and EROD data to explore and classify chemical responses

•Most chemicals have relatively low efficacy effects (<40% relative to reference chemicals) on well-characterized gene targets (e.g. CYP1A) based on histograms

•The large efficacious inductions observed with select ToxCast 320 chemicals (relative to reference chemicals) for gene targets such as GSTA2, SLC01B1, ABCG2, and ABCB1 indicate further studies are needed to explore their gene regulation

•Data demonstrate a clear suppressive effect of bile acid CDCA on cholesterol synthesis gene and PPARα induction target gene HMGCS2 that is not a hallmark of other FXR-like inducers based on these data



## **Summary & Next Steps Continued**

•'Bursts' of induction across multiple gene targets simultaneously appears to be related to the observation of chemical-related hepatocyte cellular stress

•Correlations confirm EROD and CYP1A1 relationship and suggest that CYP1A2 is similar to CYP1A1 but not well correlated with EROD activity

•Correlations demonstrate new insights into transporter gene regulation and support current thoughts regarding CYP2C9 induction

•Data demonstrate that suppression is a relatively rare event compared with induction for the selected gene targets

•The apparent correlation between diverse transporter gene targets suggests an adaptive response that is not well understood at the molecular level

•CYP2B6 appeared to be the most frequently induced gene target suggesting an important role for CAR (and PXR) in hepatocyte response to xenobiotics

Ongoing analyses

•Correlations of In vivo/in vitro data

•Relative risk factor

Clustering analysis

•Time effects: continue to explore cause/effect responses across multiple endpoints (e.g. apparent relationship between induction and cytotoxicity)

**Cell7**Direct<sup>\*\*</sup>

### Acknowledgements

<u>CellzDirect</u> Andrew Beam, BS Kimberly Freeman, MS Adam Farmer, BS Christie Baucom, BS Stephen Harper, BS Erica Deibert, BS Joy Mitchell, BS Miki Pawlowski, BS Edward L. LeCluyse, PhD Lisa Dungan, BS Chris Black, PhD

### <u>EPA</u>

Daniel Rotroff, BS David Dix, PhD Keith Houck, PhD Richard Judson, PhD David Reif, PhD John Wambaugh, PhD

<u>High Throughput Genomics</u> Ihab Botros Constantine Sabalos

<u>N. C. State University</u> Howard Bondell



Invitrogen corporation \_\_\_\_\_